Onyx Pharma Turns Down Amgen offer - Analyst Blog

By
A A A

Onyx Pharmaceuticals, Inc. ( ONXX ) rejected a $120 per share takeover bid from Amgen Inc. ( AMGN ). Management at Onyx while turning down the offer stated that it significantly undervalued the company.

Onyx is however still interested in selling itself and is on the lookout for potential bidders. Even though Onyx stated in its press release that it does not intend to communicate further regarding the $120 per share offer from biotechnology giant Amgen, we believe that it is not the end of the story.

We believe that Amgen will continue to pursue Onyx as the acquisition of the latter will further strengthen Amgen's presence in the oncology field. We believe that if the deal ultimately goes through it will do so at close to $130 per share. Onyx, a biopharma company, is engaged in the development of novel cancer therapies that target the molecular basis of the disease.

The key drugs at Onyx are Nexavar (hepatocellular carcinoma or liver cancer and advanced renal cell carcinoma or advanced kidney cancer), Stivarga (colorectal cancer and Kyprolis (multiple myeloma). Onyx is working hard to expand the label(s) of its marketed products. Onyx is also developing oprozomib for various oncology indications.

With Onyx open to offers from other bidders, it is also possible that other big players in the biopharma space like Celgene Corporation ( CELG ) and Biogen Idec Inc. ( BIIB ) express interest in Onyx resulting in a bidding war. We expect investor focus to remain on how the whole process unfolds.

Onyx currently carries a Zacks Rank #3 (Hold). However, companies such as Biogen Idec Inc. look more attractive with a Zacks Rank #1 (Strong Buy).



AMGEN INC (AMGN): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

ONYX PHARMA INC (ONXX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AMGN , BIIB , CELG , ONXX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com